Cisplatin

Generic Name: Cisplatin

Brand Names: Platinol

Drug Type: Small Molecule

Chemical Formula: Cl_₂H_₆N_₂Pt

CAS Number: 15663-27-1

Unique Ingredient Identifier: Q20Q21Q62J

Background: Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also includes carboplatin and oxaliplatin.

Indication: For the treatment of metastatic testicular tumors, metastatic ovarian tumors and advanced bladder cancer.

Associated Conditions: Advanced Ovarian Cancer, Ovarian Cancer Metastatic, Advanced Bladder cancer, Advanced Testicular cancer, Metastatic Testicular cancer

Associated Therapies: -

Clinical Trials

Primary Cytoreductive Surgery With or Without Hyperthermic Intraperitoneal Chemotherapy (HIPEC)

Phase 3

Recruiting

Conditions: Ovarian Cancer

Interventions: Drug: cisplatin

First Posted Date: 2018-12-11

Last Posted Date: 2023-09-08

Lead Sponsor: The Netherlands Cancer Institute

Target Recruit Count: 538

Registration Number: NCT03772028

Locations: 🇳🇱
Amsterdam UMC, Amsterdam, Netherlands
🇳🇱
Maastricht UMC+, Maastricht, Netherlands
🇮🇪
Mater Misericordiae University Hospital, Dublin, Dublin, Ireland

and more 25 locations

An Investigational Immuno-therapy Study of Nivolumab Given After Surgery in Non-Small Cell Lung Cancer (NSCLC) Participants With Minimal Residual Disease

Phase 2

Withdrawn

Conditions: Circulating Tumor DNA
Non-Small Cell Lung Cancer
Non-Small-Cell Lung Carcinoma

Interventions: Biological: Nivolumab
Drug: Vinorelbine
Drug: Gemcitabine
Drug: Docetaxel
Drug: Pemetrexed
Drug: Cisplatin
Drug: Carboplatin
Drug: Paclitaxel
Other: Observation

First Posted Date: 2018-12-10

Last Posted Date: 2022-03-24

Lead Sponsor: Bristol-Myers Squibb

Registration Number: NCT03770299

Gemcitabine Hydrochloride and Cisplatin With or Without Nab-Paclitaxel in Treating Patients With Newly Diagnosed Advanced Biliary Tract Cancers

Phase 3

Active, not recruiting

Conditions: Stage IIIA Distal Bile Duct Cancer AJCC v8
Stage IIIB Gallbladder Cancer AJCC v8
Stage III Intrahepatic Cholangiocarcinoma AJCC v8
Stage IIIA Gallbladder Cancer AJCC v8
Unresectable Extrahepatic Bile Duct Carcinoma
Stage III Gallbladder Cancer AJCC v8
Stage IIIB Intrahepatic Cholangiocarcinoma AJCC v8
Stage IVA Gallbladder Cancer AJCC v8
Unresectable Gallbladder Carcinoma
Unresectable Intrahepatic Cholangiocarcinoma

Interventions: Drug: Cisplatin
Drug: Gemcitabine Hydrochloride
Drug: Nab-paclitaxel

First Posted Date: 2018-12-07

Last Posted Date: 2024-11-26

Lead Sponsor: SWOG Cancer Research Network

Target Recruit Count: 452

Registration Number: NCT03768414

Locations: 🇺🇸
Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland, United States
🇺🇸
Mountain Blue Cancer Care Center, Golden, Colorado, United States
🇺🇸
Rocky Mountain Cancer Centers-Lakewood, Lakewood, Colorado, United States

and more 687 locations

Pembrolizumab in Combination With Chemotherapy and Image-Guided Surgery for Malignant Pleural Mesothelioma (MPM)

Phase 1

Recruiting

Conditions: Mesotheliomas Pleural

Interventions: Drug: Pembrolizumab
Procedure: Indocyanine Green (ICG) Image-Guided Surgery
Drug: Cisplatin
Drug: Pemetrexed

First Posted Date: 2018-11-30

Last Posted Date: 2024-07-16

Lead Sponsor: Abramson Cancer Center at Penn Medicine

Target Recruit Count: 20

Registration Number: NCT03760575

Locations: 🇺🇸
Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States

Sintilimab or Placebo With Chemotherapy in Esophageal Squamous Cell Carcinoma ( ORIENT-15 )

Phase 3

Completed

Conditions: Esophageal Squamous Cell Carcinoma

Interventions: Biological: Sintilimab
Drug: Cisplatin
Drug: Paclitaxel
Drug: Fluorouracil
Drug: Placebo

First Posted Date: 2018-11-20

Last Posted Date: 2023-10-24

Lead Sponsor: Innovent Biologics (Suzhou) Co. Ltd.

Target Recruit Count: 746

Registration Number: NCT03748134

Locations: 🇧🇪
Institut Jules Bordet, Brussels, Belgium
🇦🇺
Austin Hospital, Heidelberg, Victoria, Australia
🇧🇪
Cliniques Universitaires Saint-Luc Av., Bruxelles, Hippocrate 10, Belgium

and more 44 locations

Targeted Treatment for ALK Positive Patients Who Have Previously Been Treated for Non-squamous Non-small Cell Lung Cancer

Phase 2

Active, not recruiting

Conditions: Stage IV Lung Cancer AJCC v8
Stage IVA Lung Cancer AJCC v8
Stage IVB Lung Cancer AJCC v8
Lung Non-Squamous Non-Small Cell Carcinoma

Interventions: Drug: Alectinib
Drug: Crizotinib
Drug: Brigatinib
Drug: Ceritinib
Drug: Lorlatinib
Drug: Carboplatin
Drug: Cisplatin
Drug: Ensartinib
Drug: Pemetrexed

First Posted Date: 2018-11-13

Last Posted Date: 2024-11-13

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 10

Registration Number: NCT03737994

Locations: 🇺🇸
Miller-Dwan Hospital, Duluth, Minnesota, United States
🇺🇸
Fairview Southdale Hospital, Edina, Minnesota, United States
🇺🇸
Grady Memorial Hospital, Delaware, Ohio, United States

and more 487 locations

Atezolizumab Before and/or With Chemoradiotherapy in Immune System Activation in Patients With Node Positive Stage IB2, II, IIIB, or IVA Cervical Cancer

Phase 1

Active, not recruiting

Conditions: Stage II Cervical Cancer AJCC v8
Cervical Adenocarcinoma
Cervical Squamous Cell Carcinoma
Stage IVA Cervical Cancer AJCC v8
Cervical Adenosquamous Carcinoma
Stage IIA Cervical Cancer AJCC v8
Stage IIA2 Cervical Cancer AJCC v8
Stage IIB Cervical Cancer AJCC v8
Stage IB2 Cervical Cancer AJCC v8
Stage IIIB Cervical Cancer AJCC v8

Interventions: Drug: Atezolizumab
Radiation: Brachytherapy
Drug: Cisplatin
Radiation: Radiation Therapy

First Posted Date: 2018-11-13

Last Posted Date: 2024-10-15

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 40

Registration Number: NCT03738228

Locations: 🇺🇸
Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, United States
🇺🇸
Women and Infants Hospital, Providence, Rhode Island, United States
🇺🇸
University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania, United States

and more 13 locations

Systemic Immune Checkpoint Blockade and Intraperitoneal Chemo-Immunotherapy in Recurrent Ovarian Cancer

Phase 1

Recruiting

Conditions: Ovarian Cancer Recurrent

Interventions: Drug: Rintatolimod
Drug: Pembrolizumab
Drug: Cisplatin

First Posted Date: 2018-11-08

Last Posted Date: 2024-06-05

Lead Sponsor: Robert Edwards

Target Recruit Count: 45

Registration Number: NCT03734692

Locations: 🇺🇸
Magee-Womens Hospital of UPMC, Pittsburgh, Pennsylvania, United States

Durvalumab+ Gemcitabine/Cisplatin (Neoadjuvant Treatment) and Durvalumab (Adjuvant Treatment) in Patients With MIBC

Phase 3

Active, not recruiting

Conditions: Muscle Invasive Bladder Cancer

Interventions: Drug: Durvalumab
Drug: Gemcitabine
Drug: Cisplatin

First Posted Date: 2018-11-06

Last Posted Date: 2024-11-28

Lead Sponsor: AstraZeneca

Target Recruit Count: 1063

Registration Number: NCT03732677

Locations: 🇻🇳
Research Site, Hochiminh, Vietnam

Study of Avelumab and Cetuximab Plus Gemcitabine and Cisplatin in Participants With NSCLC

Phase 2

Completed

Conditions: Squamous Non-Small Cell Lung Cancer

Interventions: Drug: Avelumab
Drug: Cetuximab
Drug: Gemcitabine
Drug: Cisplatin
Drug: Carboplatin

First Posted Date: 2018-10-24

Last Posted Date: 2022-06-06

Lead Sponsor: Merck KGaA, Darmstadt, Germany

Target Recruit Count: 43

Registration Number: NCT03717155

Locations: 🇭🇺
Petz Aladar Megyei Oktato Korhaz - Pulmonologiai Osztaly, Gyor, Hungary
🇭🇺
Tudogyogyintezet Torokbalint - Onkopulmonologiai es Jarobeteg centrum, Torokbalint, Hungary
🇪🇸
Hospital Universitari Vall d'Hebron - Dept of Oncology, Barcelona, Spain

and more 17 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy